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Abstract
Background: Previous evaluations of the cost-effectiveness of the cyclooxygenase-2 selective
inhibitor celecoxib (Celebrex, Pfizer Inc, USA) have produced conflicting results. The recent
controversy over the cardiovascular (CV) risks of rofecoxib and other coxibs has renewed interest
in the economic profile of celecoxib, the only coxib now available in the United States. The
objective of our study was to evaluate the long-term cost-effectiveness of celecoxib compared with
nonselective nonsteroidal anti-inflammatory drugs (nsNSAIDs) in a population of 60-year-old
osteoarthritis (OA) patients with average risks of upper gastrointestinal (UGI) complications who
require chronic daily NSAID therapy.
Methods:  We used decision analysis based on data from the literature to evaluate cost-
effectiveness from a modified societal perspective over patients' lifetimes, with outcomes
expressed as incremental costs per quality-adjusted life-year (QALY) gained. Sensitivity tests were
performed to evaluate the impacts of advancing age, CV thromboembolic event risk, different
analytic horizons and alternate treatment strategies after UGI adverse events.
Results: Our main findings were: 1) the base model incremental cost-effectiveness ratio (ICER)
for celecoxib versus nsNSAIDs was $31,097 per QALY; 2) the ICER per QALY was $19,309 for a
model in which UGI ulcer and ulcer complication event risks increased with advancing age; 3) the
ICER per QALY was $17,120 in sensitivity analyses combining serious CV thromboembolic event
(myocardial infarction, stroke, CV death) risks with base model assumptions.
Conclusion: Our model suggests that chronic celecoxib is cost-effective versus nsNSAIDs in a
population of 60-year-old OA patients with average risks of UGI events.
Background
Nonselective nonsteroidal anti-inflammatory drugs (nsN-
SAIDs) are widely used to treat acute and chronic pain,
including the symptoms of osteoarthritis (OA). The most
clinically important adverse events associated with nsN-
SAID use, ulcer perforations, obstructions, and bleeds
(collectively POBs), can be life-threatening and constitute
a major public health problem with a large cost to society
[1-3]. Uncomplicated peptic ulcers and dyspepsia are not
as important clinically as POBs, but, because they are the
most prevalent nsNSAID adverse events, their total impact
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in healthcare costs, activity restrictions, production losses,
pain, and discomfort is considerable [4-10].
The cyclooxygenase-2 selective inhibitor celecoxib reduces
the risks of nsNSAID-induced gastropathy without com-
promising clinical efficacy. However, evaluations of the
cost-effectiveness of celecoxib have produced conflicting
results owing mainly to differences in model structures,
populations at risk, probabilities, cost-effectiveness indi-
cators, and relative drug prices across countries.
The objective of our study was to evaluate the cost-effec-
tiveness of the long-term use of celecoxib compared with
nsNSAIDs in a population of 60-year-old OA patients
with average risks of upper gastrointestinal (UGI) compli-
cations who require chronic daily NSAID therapy. We
assume that acetaminophen is contraindicated or other-
wise inferior to NSAID therapy in these patients. Ours is
the only coxib evaluation that uses UGI ulcer probabilities
from a population comprised only of OA patients, and
accounts for reductions in the prices of celecoxib and
over-the-counter (OTC) omeprazole after loss of patent
protection. Although there have been other lifetime coxib
models, only ours extrapolates probabilities and models
health states based on long-term evidence from the litera-
ture and evaluates celecoxib independently [11-13]. In
sensitivity testing, the distinctive features of our study are
its evaluations of a comprehensive indicator of serious
cardiovascular (CV) thromboembolic risk, alternate treat-
ment regimens after UGI adverse events, and differences
in the lengths of the analytic horizon.
Methods
Cost-effectiveness analysis is used to compare celecoxib
(Celebrex, Pfizer Inc, USA) at 200 mg/d, the recom-
mended OA dose, with a combination of diclofenac at
100 mg/d and naproxen at 1000 mg/d. The target popula-
tion is 60-year-old patients with moderate to severe OA
requiring chronic daily NSAIDs. The outcomes of the
model are incremental costs per quality-adjusted life-year
(QALY) gained from reductions in symptomatic peptic
ulcers, perforations, obstructions, bleeding ulcers (collec-
tively PUBs), and nonulcer dyspepsia. CV thromboem-
bolic events and efficacy in relieving OA symptoms are
excluded in the base model on the assumption that there
are no differences in these outcomes between celecoxib
and nsNSAIDs [14-17].
Model
The structure of the model used in this study is presented
in Figure 1. The problem is structured in Microsoft Excel
2002 as a decision tree with 21 one-year periods. Our lit-
erature-based UGI adverse events were comprised of dis-
crete and short-duration NUD, POB and peptic ulcer
events in some patients and long-term chronic NUD and
PUD health states in others. The model allowed for mul-
tiple POB and PUB events to recur in time for patients
whose short-term discrete events were initially resolved.
Patients on nsNSAIDs switch in perpetuity to celecoxib
and patients in both cohorts add chronic daily omepra-
zole after experiencing nonulcer dyspepsia-like symptoms
or a PUB event [12]. This assumption recognizes the
heightened UGI risks after PUB events, which compound
older patients' already high cumulative risks with long-
term nsNSAID therapy, the risk that nonulcer dyspepsia
might progress to a peptic ulcer, and the potential benefits
from symptom relief [1,18,19]. In sensitivity analysis, we
include 4 alternate post-event treatment approaches also
used in clinical practice.
A lifetime analytic horizon is used because many OA suf-
ferers are long-term NSAID users, with high cumulative
risks of gastropathy, and some adverse events in the
model affect health states for extended periods [20]. Our
societal perspective, modified to exclude indirect costs,
does not differentiate between patient and insurer costs
and is compatible with our use of a lifetime horizon.
We assume that all members of the celecoxib and nsN-
SAID treatment groups are aged 60 years at the outset and
all die in the base model at age 81 years, except those with
an adverse gastrointestinal (GI) event resulting in prema-
ture death before the end of the 21-year lifetime horizon
[12].
We conducted literature searches to obtain representative
clinical adverse event rates and information on the long-
term courses of health states after adverse events. We
Schematic representation of the study model Figure 1
Schematic representation of the study model. nsN-
SAID, nonselective nonsteroidal anti-inflammatory drug; 
NUD, nonulcer dyspepsia-like composite; OA, osteoarthritis; 
PPI, proton pump inhibitor; POB, perforation, obstruction, 
bleeding ulcer; UGI, upper gastrointestinal.BMC Gastroenterology 2007, 7:25 http://www.biomedcentral.com/1471-230X/7/25
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sought UGI adverse event rates for patients using the
doses of celecoxib and nsNSAIDs recommended for OA
patients. Celecoxib is more commonly used for the treat-
ment of the symptoms of OA rather than rheumatoid
arthritis. Our search strategies are outlined in more detail
in Appendix I.
Probabilities
Our probabilities for POBs and peptic ulcers are based on
event rates in the Successive Celecoxib Efficacy and Safety
Study-1 (SUCCESS), the only celecoxib clinical trial that
was conducted in a population of OA patients and that
used POBs and PUBs as end points [16]. This 12-week
trial with a total of 13,274 patients allowed the use of con-
comitant aspirin (7.1% baseline prevalence) but excluded
high-risk patients with active or recent GI disease, histo-
ries of multiple peptic ulcers, various other comorbidities,
and those requiring corticosteroids or chronic gastropro-
tective agents. Patients with a previous history of ulcers
comprised 4.1% of the SUCCESS population, about half
the proportions in 2 other major coxib clinical trials, the
Celecoxib Long-Term Arthritis Safety Study (CLASS) [21]
and the Vioxx Gastrointestinal Outcomes Research study
(VIGOR) [22].
The model's POB probabilities per 100 patient-years are
0.8 for nsNSAIDs and 0.1 for celecoxib, representing a
crude relative risk reduction (RRR) for celecoxib of 0.875
[16]. This RRR is consistent with those from a pooled
analysis of 14 arthritis clinical trials and a 42-week retro-
spective cohort study of hospitalized POBs [23,24]. Our
symptomatic ulcer probabilities per 100 patient-years
adapted from SUCCESS are 1.2 for nsNSAIDs and 0.9 for
celecoxib (RRR = 0.25).
The base model extrapolates these probabilities over 21
years to calculate POB cumulative incidence rates of
15.5% for the naproxen-diclofenac combination and
2.1% for celecoxib, and respective peptic ulcer rates of
22.4% and 17.3% (Table 1) [24-29]. Our assumption that
risks are constant over time, which is intended to produce
a conservative base-case incremental cost-effectiveness
ratio (ICER) for celecoxib, is relaxed in sensitivity testing
to allow, more realistically, for increased risk with advanc-
ing age. Patients who experience a PUB event in the model
are assumed to be 2.7 times more likely than others to suf-
fer a future peptic ulcer or POB [18,25,28,30,31].
The nonulcer GI adverse events of NSAIDs, consisting of
dyspepsia (upper abdominal pain or discomfort), nausea,
diarrhea, heartburn, constipation, and flatulence, are rele-
vant to economic evaluations because they diminish
patients' quality of life and result in increased treatment
costs. However, we model only for dyspepsia-like symp-
toms (including nausea), mainly due to data limitations.
Our clinical probabilities for dyspepsia-like symptoms of
12.0% (95% confidence interval [CI], 9.9%–14.0%) for
an nsNSAID and 7.8% (95% CI, 6.0%–9.5%) for
celecoxib 200 mg/d are based on moderate to severe dys-
pepsia, abdominal pain, or nausea event rates in a pooled
analysis of trials in arthritis patients (Table 1) [32]. We
adopt these probabilities for our lifetime horizon based
on findings that cumulative incidence curves for dyspep-
sia begin to plateau in trials, may be essentially flat
beyond a year, and are unaffected by aging [32-34]. A sec-
ond pooled analysis comparing OA patients taking
celecoxib 200 mg/d or an nsNSAID found near-identical
relative risks (RR) for a similar composite dyspepsia-like
end point [35].
QALYs, utilities, and durations of health states
We assume a base utility value of 0.67 for OA patients
without UGI problems and apply utility adjustments for
adverse events as deductions from the base (Table 2)
[36,37]. The base utility value of 0.67 reflects the fact that
the average health of older OA patients, who have a high
prevalence of comorbid conditions, is considerably below
perfect health, which carries a utility value of 1.0. The
annual adjustments for adverse events are the product of
the loss of utility from the adverse event and the length of
the associated health state expressed as a fraction of a year.
Our disutilities of 0.13 for dyspepsia and peptic ulcers are
based on individuals with moderate to severe dyspepsia
aged 59 years or more [38]. We corroborated this peptic
ulcer disutility by comparing differences in average Health
Utility Index values for older OA patients with and with-
out ulcers in a large Canadian database [39]. Disutilities
for hospitalized cases were adapted from the literature,
with the lengths of inpatient POB and peptic ulcer health
states set at averages for such cases in a Maryland hospital
database [40,41]. We factored in additional disutilities for
35% of POB patients with assumed prior symptoms of
dyspepsia [42-45].
NSAID-associated nonulcer dyspepsia consists of single
events, series of periodic events, or essentially continuous
symptoms. Our modeling assumption is that 55% of dys-
pepsia patients experience chronic daily symptoms,
whereas the remaining patients experience a single 35-day
episode of symptoms [12,46-54]. The long-term propor-
tion assumed to be chronic is consistent with the findings
of 2 systematic reviews and other long-term studies
[33,52,55,56].
The long-term course of peptic ulcer disease is complex,
with high rates of peptic ulcer and ulcer-symptom recur-
rence and chronicity [4,12,46,54,57-59]. Our simplified
modeling assumption is that the combined point preva-
lence of patients with active symptomatic ulcers and pos-BMC Gastroenterology 2007, 7:25 http://www.biomedcentral.com/1471-230X/7/25
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tulcer symptoms is 50% of lifetime prevalent ulcers
developed over the analytic horizon of the model [60].
This means that the cumulative incidence rate in our
model would average 6.1% over the analytic horizon in
patients in the nsNSAID treatment arm compared with
4.7% in those in the celecoxib treatment arm.
To test this assumption, we analyzed the prevalence of
ulcers among OA patients over the age of 59 years as deter-
mined by a Canadian population-based survey [39].
Seven percent of such patients reported having a current
physician-diagnosed ulcer of at least 6 months' duration.
This means that the steady state prevalence in a popula-
tion of OA patients in the community, who are not neces-
sarily NSAID users, exceeds the average prevalence for
NSAID users in our base model.
Costs and other data
We assume that generic celecoxib will be available in
2013, the year of patent expiry, and that the price will be
55% lower than that of Celebrex, with a range of 30% to
80% for sensitivity testing (Table 3) [61-64]. We employ
only the estimated generic price in our model after mid
2013. This is consistent with our approach of using prices
of generic nsNSAIDs and OTC omeprazole in the model.
Average inpatient hospital costs, lengths of stay, and vari-
ous hospital statistics were derived from a Maryland inpa-
tient database [40]. We employed principal diagnosis
codes and diagnosis-related groups to identify relevant
cases and restricted our analyses to patients aged 60 years
or more. In the Maryland system, each hospital's charges
are based on standardized overhead allocation methods,
regulated to reflect the costs (including capital) of services
provided, and charge rates apply to all payers without dis-
crimination or discounting. The average cost per adjusted
admission in Maryland approximates the national aver-
age.
Results
Incremental treatment costs and benefits of $4,055 and
0.1304 QALYs resulted in a base-case celecoxib versus
nsNSAID ICER of $31,097 per QALY, which falls within
the range normally considered to be cost-effective (Table
4). The 21-year treatment costs for average patients in the
celecoxib and nsNSAID initial treatment groups were
$14,151 and $10,096, respectively, whereas the corre-
sponding QALYs were 10.2982 and 10.1678.
Sensitivity testing
Uncertainty
One-way sensitivity analysis results for clinical and eco-
nomic variables showed that the ICER rose above $60,000
per QALY (our standard for cost effectiveness) for only 2
of the variables when ranged over the values in Tables 1,
2, or 3, the nsNSAID peptic ulcer and POB probabilities
[65]. Other relatively influential variables in 1-way analy-
ses were (in descending order of influence): the celecoxib
price, and the event probabilities for a celecoxib peptic
ulcer, nsNSAID dyspepsia, and a celecoxib POB.
Table 1: Clinical probabilities
Clinical probabilities Base case (range) Reference
Dyspepsia composite
nsNSAIDs 12.0% (9.9%–14.0%) [32]
Celecoxib 7.8% (6.0%–9.5%) [32]
POB 21-year cumulative incidence
nsNSAIDs 15.5% (4.1%–24.8%) [16,24-29]
Celecoxib 2.1% (0.0%–6.1%) [16,24-29]
Symptomatic peptic ulcer 21-year cumulative incidence
nsNSAIDs 22.4% (10.0%–33.7%) [16,24-29]
Celecoxib 17.3% (10.0%–24.0%) [16,24-29]
PUB 21-year cumulative incidence
nsNSAIDs 34.6% (19.0%–47.3%) [16,24-29]
Celecoxib 19.0% (10.0%–27.2%) [16,24-29]
Age-related increase in PUB risk per year 4.3% (2.5%–6.1%) [18,25,27,28,71,72]
PUB risk multiplier for prior PUB event 2.7 (1.5–4.7) [18,25,28,30,31]
Hospitalization rate for POBs 90% (80%–100%) [145-150]
Mortality rate as percent of POBs 8.0% (5.0%–14.0%) [151-159]
POB with prior dyspepsia 35% (20%–50%) [42,44,45]
Ratio active ulcers and symptoms to lifetime-prevalent peptic ulcers 50% (0%–65%) See text
Ratio chronic to lifetime-prevalent nonulcer dyspepsia 55% (0%–75%) [12,33,52,55,56]
nsNSAID, non-selective non-steroidal anti-inflammatory drugs; PUB, symptomatic peptic ulcers, perforations, obstructions, bleeding ulcers; POB, 
perforation, obstruction, bleeding ulcer; PPI, proton pump inhibitor.BMC Gastroenterology 2007, 7:25 http://www.biomedcentral.com/1471-230X/7/25
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Univariate analysis of the sensitivity of the ICER to pro-
portional changes in economic and clinical variables
identified the following important variables listed in
declining order of their impact on the ICER, along with
their threshold values and the proportional changes in
each required to attain threshold: celecoxib cost per pill,
$3.72 (+41%) and 21-year probabilities of nsNSAID dys-
pepsia, 0.0743 (-38%); nsNSAID peptic ulcer, 0.126 (-
44%); nsNSAID POB, 0.061 (-61%); and celecoxib dys-
pepsia, 0.1295 (+66%). Hence, the results are robust for
all but very large proportional changes.
In addition to the above sensitivity analysis for uncer-
tainty, we assessed variants of the base model in which: 1)
risks of PUBs increase with age; 2) the length of the ana-
lytic horizon is varied; 3) treatment regimens are altered
after adverse events; and 4) different serious CV throm-
boembolic risks are assumed.
Risks with aging
Advanced age is a well-documented risk factor for PUBs
[1,3,31,66-70]. In this sensitivity analysis, we assumed
that PUB risks increase by 4.3% per year after age 60 years
[18,25,27,28,71,72]. The assumption implies that PUB
risks at age 81 years are 2.3 times those at baseline for
patients aged 60 years.
The ICER declined to $19,309 when age-related increases
in PUB risks were factored into the base-model assump-
tions (Table 5). The cumulative incidence rates were
28.3% for PUBs in the celecoxib initial treatment group
and 48.9% in nsNSAID group, with corresponding POB
cumulative incidence rates of 3.3% and 23.4%, respec-
tively. When dyspepsia was included, about 60.9% of
nsNSAID patients had at least 1 UGI adverse event over
the analytic horizon compared with 36.1% of celecoxib
patients.
Analytic horizon
The ICER declined 74.9% from $124,100 for a 1-year
model to $31,097 for the 21-year model without age risks
(Table 5). In the absence of the patent expiration effect,
the ICER would have decreased 53.8% from $124,100 to
$57,363 in a 21-year model. The ICER declined below
$60,000 per QALY as of year 13 of the analytic horizon in
the base case, and year 11 in the sensitivity analysis in
which the risk of a PUB event increased with advancing
age.
Alternative treatment approaches after a UGI adverse event
The base model switched patients initially taking
celecoxib or an nsNSAID to regimens of celecoxib plus a
proton pump inhibitor (PPI) after dyspepsia or a PUB, an
approach that is clinically reasonable given the elevated
risks of PUBs and perhaps death after such events. In sen-
sitivity analysis, we also assessed 4 alternate secondary
strategies to determine whether the ICER for celecoxib ver-
sus an nsNSAID would remain below $60,000 per QALY
for other possible postevent treatment regimens.
The 4 alternate treatment strategies were: 1) all patients
continue on their original treatment regimen, after under-
going temporary courses of PPI healing therapy for PUBs
and Helicobacter pylori eradication therapy, as necessary; 2)
all patients continue on celecoxib or their nsNSAID and
commence PPI cotherapy for the rest of their lives after
PUBs; 3) all nsNSAID patients switch to celecoxib plus PPI
and celecoxib patients add a PPI for the rest of their lives
post-PUB, but nonulcer dyspepsia patients continue on
their original treatment regime; and 4) all nsNSAID
patients add a PPI after PUBs with all other treatments
unchanged after events.
Celecoxib is cost-effective at the sub-$60,000 per QALY
level for models incorporating each of the 4 post event
treatment regimens (Table 5) [37,50,73-77]. Clinical
Table 2: Utilities and QALY losses for simple health states
Simple health states QALY losses Reference
Dyspepsia (-0.13)
Resolved events (35 days) -0.01247 (-0.005753 to -0.01496) [38]
Chronic per year -0.13 (-0.06 to -0.156) [38]
Symptomatic peptic ulcers (-0.13)
Resolved events (35 days) -0.01247 (-0.005753 to -0.01496) [38]
Chronic per year -0.13 (-0.06 to -0.156) [38]
Hospitalization stays
POB (ALOS = 5.56 days) -0.007926 (-0.00634 to -0.009511) [12,40,41]
Peptic ulcers (ALOS = 4.10 days) -0.005868 (-0.004694 to -0.007042) [12,40,41]
Outpatient POB ER visit -0.001397 (-0.001118 to -0.001676) [41]
Endoscopy (-0.4325) -0.00119 (-000952 to -0.001428) [41]
Premature POB death per year -0.67 (-0.536 to -0.804) [36,37]
QALY, quality-adjusted life year; POB, perforation, obstruction, bleeding ulcer; ALOS, average length of stay; ER, emergency room. QALY benefits 
discounted 3% annually.BMC Gastroenterology 2007, 7:25 http://www.biomedcentral.com/1471-230X/7/25
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probabilities were not sufficiently robust to support a full
comparison of ICERs between the alternate regimes.
Depletion of susceptibles
We also tested an alternate assumption that our SUCCESS
POB probabilities were too high for constant-risk extrap-
olation in our model owing to depletion of susceptibles,
the theory that risks are higher in the first few months of
NSAID use. The ICER in the base case rose to $40,841 per
QALY in a base case model with a 30% reduction in POB
risks. The ICER further rose to $45,955 per QALY when we
extended the 30% reduction to peptic ulcer probabilities
and POBs.
Risks of serious CV thromboembolic events
Our serious CV thromboembolic event (myocardial inf-
arction [MI]), stroke, CV death) costs, and disutilities take
into account the impact of the initial event and of subse-
quent effects, as described in more detail in Appendix II.
Our probabilities of such events are based on a meta-anal-
ysis of serious CV thromboembolic risk that found event
rates of 1.01 per 100 patient-years in celecoxib patients
and 1.23 per 100 patient-years in nsNSAID users, with a
RR of 0.86 (95% CI, 0.59–1.26) [15]. The ICER in our
model declines to $17,120 per QALY when these risks are
included, and our results were robust when the RR was
varied over all but the extreme upper end of the 95% CI.
Discussion
We conducted a cost-effectiveness analysis of long-term
celecoxib use compared with nsNSAID use in OA patients.
Some of our key assumptions, not adequately addressed
in previous models, include a more realistic analytic hori-
zon for UGI adverse events in OA patients with extrapola-
tion and health states based on long-term evidence from
the literature, prescription drug prices influenced by ter-
mination of patent protection, and ulcer probabilities
derived from an OA population.
Our base-case celecoxib ICER of $31,097 per QALY sug-
gests cost-effectiveness for 60-year-old OA patients with
average baseline UGI risks, 7.1% of whom were taking
aspirin for cardioprophylaxis. The ICER declines to
$19,309 when account is taken of the increase in PUB
risks with advancing age. The ICER, including risks of seri-
ous CV thromboembolic events, is $17,120 for a model
without age-related risks, and ICERs ranged from $38,807
to $46,192 per QALY in sensitivity analysis with alternate
post adverse event treatment strategies.
Our model suggests that the use of short analytic horizons
to evaluate long-term celecoxib therapy in OA patients
results in biased findings [20,78,79]. The diverging cumu-
lative incidence of PUBs in patients in our model's 2 ini-
tial treatment groups results in progressively larger
Table 3: Cost* and other data summarized
Base case (range) Reference
Celecoxib 200 mg/d $2.64 ($2.11–$3.17) http://drugstore.com
Naproxen 1000 mg/d $0.45 ($0.36–$0.54) http://drugstore.com
Diclofenac 100 mg/d $0.64 ($0.51–$0.77) http://drugstore.com
Omeprazole (over-the-counter) 20 mg/d $0.60 ($0.48–$0.72) http://drugstore.com
Price reduction generic celecoxib 55% (30%–80%) [61,63]
POB inpatient-hospital plus physician (ALOS = 5.56 days) $12,796 ($10,234–$15,355) [12,40]
POB outpatient-hospital plus physician $1,813 ($1,450–$2,176) [12,160,161]
Peptic ulcer inpatient-hospital plus physician (ALOS = 4.10 days) $7,353 ($5,882–$8,824) [12,40]
Peptic ulcer outpatient discrete event including endoscopy $1,554 ($1,243–$1,865) [12,160,161]
Dyspepsia outpatient initial event including endoscopy $1,208 ($966–$1,450) [12,160,161]
Ongoing annual medical and laboratory costs chronic peptic ulcer or dyspepsia $130 ($104–$156) [160], Estimates RBRVS
POB proportion of surgery DRGs 14.2% [40]
POB admissions through emergency 89.7% [40]
Proportion of peptic ulcer patients admitted to hospital 4.37% [40]
Discount rate for costs and QALYs 3.0%
Price inflation rate 2.0%
POB, perforation, obstruction, bleeding ulcer; ALOS, average length of stay; RBRVS, resource-based relative value scale; DRGs, diagnosis-related 
groups. *Drug prices as of February 2006.
Table 4: Base model ICER
QALYs Costs ICER
nsNSAID 10.1678 $10,096
Celecoxib 10.2982 $14,151
Net incremental 0.1304 $4,055 $31,097
ICER, incremental cost-effective ratio; QALY, quality-adjusted life 
year; nsNSAID, nonselective nonsteroidal anti-inflammatory drugs.BMC Gastroenterology 2007, 7:25 http://www.biomedcentral.com/1471-230X/7/25
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differences between comparators' incidences of subse-
quent PUB events, their ongoing disutilities from chronic
peptic ulcers, and their continuing expenses from higher-
cost post-PUB treatment regimens. Additionally, trun-
cated horizons neither capture the full QALY impact of the
higher mortality rates in nsNSAID patients nor take into
account future celecoxib patent expiration and the related
price decreases. Finally, if the risk of PUBs increases with
advancing age, as the evidence suggests, the impact of this
factor would be muted by short analytic horizons.
Previous coxib evaluations do not appear to have
accounted for the patent expiration of celecoxib in 2013
or that of omeprazole in 2002, although PPIs are impor-
tant drivers of costs in some models and the current OTC
price represents a reduction of more than 75% in the
United States.
Our main results are based on regimens of daily nsN-
SAIDs, whereas intermittent therapy provides adequate
relief of OA symptoms for some users of chronic nsN-
SAIDs in the community. Additionally, some candidates
for continuous nsNSAID therapy may interrupt treatment
periodically as a strategy to lower MI and stroke risks, even
though they suffer disutilities from symptom relief fore-
gone during washout periods. Published coxib evalua-
tions have assumed continuous nsNSAID use because
evidence-based probabilities for intermittent treatment
regimens are unavailable and myriad patterns of intermit-
tent use are possible [80].
We assessed frequent but intermittent nsNSAID use,
which we defined as a minimum of 104 days of therapy
per year or approximately 2 days per week for 52 weeks.
Our celecoxib versus nsNSAID ICERs were $43,000 per
QALY or lower depending on the assumed behavior of
UGI risks during intermittent use, number of therapy
days, and other factors. Hence, our model's results are not
contingent on a restrictive assumption of continuous use.
Six evaluations from Europe, Asia, and Canada suggest a
favorable economic profile for celecoxib [13,81-85].
However, 5 of these studies with a similar evaluation
framework incorporate nsNSAID ulcer probabilities con-
siderably higher than those in the major trials, and inter-
national differences in drug prices and health system costs
also limit the scope for generalizing these findings to
other countries [16,21,22]. Two American studies suggest
that celecoxib may be cost-effective compared with an
nsNSAID [86,87].
Conversely, an influential American study evaluating a
celecoxib-rofecoxib hybrid and a Canadian study compar-
ing celecoxib with ibuprofen and diclofenac produced
base-case ICERs far outside ranges considered to be cost-
effective, although both found that coxibs might be cost-
effective in high-risk populations [12,37]. These 2 studies
of OA and rheumatoid arthritis patients not taking low-
dose aspirin relied on controversial longer-term follow-up
findings from the CLASS trial for critical assumptions [88-
95]. These assumptions from CLASS, the earliest celecoxib
trial with both POBs and PUBs as end points, conflict with
current evidence, including findings from subsequent
coxib trials.
Differences in assumptions and model parameters created
most of the inconsistencies between the results of the
American study by Spiegel and coauthors and our find-
ings. Our model used the SUCCESS trial results as the
basis for the key celecoxib and nsNSAID ulcer probabili-
ties, whereas Spiegel used those for a coxib hybrid with
predominant weightings from rofecoxib trials and CLASS,
with its supratherapeutic doses of celecoxib. More impor-
tant, Spiegel's results were driven by an assumption that
the annual new patient incidence of PUBs would decrease
by 35% per year over its entire 21-year analytic horizon.
This pivotal assumption was based on a special-case com-
parison of the POB incidence rates of nsNSAID patients in
the first 6 months and the remaining observational period
Table 5: Summary of base model and special sensitivity analysis results
Model features No age risks Sensitivity analyses with age risks
Lifetime models
Base model $31,097 $19,309
Alternative treatments after UGI events models $38,807–$46,192 $26,201–$31,777
CV thromboembolic risks 1[15] $17,120 $7,923
Other analytic horizons
1 year $124,100 $124,100
5 years $108,549 $104,104
8 years $93,420 $85,534
11 years $67,812 $58,459
12 years $61,191 $51,521
UGI, upper gastrointestinal; CV, cardiovascular.BMC Gastroenterology 2007, 7:25 http://www.biomedcentral.com/1471-230X/7/25
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of the CLASS trial [12]. Under the assumed decay func-
tion, the cumulative incidence rate of PUBs in nsNSAID
patients was 2.6% in the first year and totaled only 7.2%
in the 21-year horizon of the Spiegel model. In contrast,
the 21-year incidence rate of 34.6% in our base model was
almost triple the upper end of the range in Spiegel's sensi-
tivity test. The differences in the ulcer probabilities are the
most important difference between the Spiegel model and
the model reported here. Other limitations of the Spiegel
model are that it did not take into account any of the fol-
lowing: increases in UGI risks from the aging of its cohorts
over the 21-year analytic horizon, increased UGI risks
after PUB events, and the price reductions from the expir-
ies of patents on celecoxib and omeprazole.
The data in our review of coxib and nsNSAID trials rang-
ing in duration from 1 to 3 years support the generaliza-
tion that PUB and POB risks are constant in long clinical
trials [22,30,31,96,97]. Hence, we believe that the weight
of previous and newer trial evidence supports the conclu-
sion of the CLASS authors and others that the POB and
PUB event rates observed in nsNSAID patients in the
longer follow-up portion of CLASS are biased and that the
decline in POB rates in this trial was aberrant
[66,88,93,94,98]. The long-term decay function in the
Spiegel model also conflicts with evidence from observa-
tional studies ranging in length from 2 to 15 years [25-
29,99-102].
The use of ulcer event rates from the longer-term CLASS
trial is 1 reason for the inconsistency of Maetzel and col-
leagues' Canadian model with our results [37,80]. The
RRRs in PUB rates range from 47% to 50% for coxibs ver-
sus nsNSAIDs in typical trials [16,22,96,97]. However, for
celecoxib compared with diclofenac and ibuprofen, Mae-
tzel's PUB RRs from the CLASS trial were 0.975 and 0.362,
respectively (versus our 0.50 compared with nsNSAIDs)
and his POB RRs were 0.917 and 0.386, respectively (ver-
sus our 0.125 compared to nsNSAIDs) [37,80]. Addition-
ally, Maetzel assumed relative dyspepsia risks of 1.00
(versus our 0.65) and relative MI risks of 1.39 to 1.44 (ver-
sus our equality of serious CV thromboembolic event
risks). Other important differences between the Maetzel
model and ours are its 5-year horizon and absence of pat-
ent expiration effects, lower probabilities of death from
initial compared with repeat POBs, and withdrawal of
95% of POB patients from further NSAID treatment
[37,80].
Probabilities obtained from the SUCCESS trial and our
modeling decisions tend to be conservative. Relevant deci-
sions include the assumed independence of PUB risks and
age in the base model and the exclusion of indirect costs.
The doses used in the SUCCESS trial tended to favor nsN-
SAIDs: one half the celecoxib patients received double the
dose recommended for OA patients, whereas the 100-mg
daily diclofenac dose was less than the maximum dose
approved for OA patients in participating countries
[16,18,21,23,103]. Also, diclofenac, the main comparator
in the SUCCESS trial, is one of the less toxic nsNSAIDs
[104,105].
The results of our model cannot necessarily be generalized
to all populations of OA patients. Furthermore, our results
are contingent both on the validity of the short-term prob-
abilities in the model and of our approach to extrapolat-
ing them over a 21-year period. Although extrapolation is
commonly employed in, and generally recommended for,
cost-effectiveness analyses of pharmaceuticals, it engen-
ders uncertainties that increase with the length of the
period [106].
According to 3 competing theories, CV thromboembolic
risks may be associated with individual NSAIDs, coxibs as
a class, or all nonaspirin NSAIDs as a class. Incremental
cost-effectiveness analysis as employed in this article deals
only with differences in risks between nsNSAIDs and
celecoxib.
One limitation of the clinical trials in which celecoxib ver-
sus nsNSAID CV thromboembolic events have been stud-
ied to date, including those in the meta-analysis we used
to account for possible differences in CV risks, is that none
were originally designed for the primary purpose of
assessing differences in these events between treatment
groups and they tend to be underpowered for this pur-
pose. Furthermore, the follow-up periods in most of the
clinical trials in the meta-analysis that we used were
shorter than one year in duration. However, longer obser-
vational studies of CV risk are consistent with a similarity
of celecoxib and nsNSAID risks, even though they often
employ MI end points, which generally favor nsNSAIDs in
clinical trials [107-121]. Current evidence about relative
CV thromboembolic risk is controversial and does not
exclude the possibility that celecoxib at OA doses is asso-
ciated either with elevated or decreased risks of CV throm-
boembolic events versus nsNSAIDs.
Conclusion
Our model suggests that the long-term use of celecoxib is
cost-effective versus nsNSAIDs in a population of 60-year-
old OA patients with average risks of UGI events.
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Appendix 1 – literature search strategy
To obtain clinical probabilities for symptomatic ulcers
and POBs, we searched PUBMED for all clinical trials
comparing celecoxib versus nsNSAIDs at recommended
doses for the treatment of OA patients with symptomatic
peptic ulcers or ulcer complications as end points. Key
words used in the search were "clinical trial" or "RCT"
(randomized clinical trial); "osteoarthritis"; "celecoxib,"
"ulcer," "hemorrhage," "haemorrhage," "bleed," "bleed-
ing," "perforation," "POB," "PUB", or "PUD" (peptic
ulcer disease). We reviewed the resultant abstracts,
obtained the full articles as warranted, and reviewed arti-
cle references. SUCCESS was the only clinical trial with the
required end points that exclusively involved OA patients.
The SUCCESS trial partially fulfilled our dosage objective,
but one half of the celecoxib patients received double the
200-mg daily dose recommended for OA patients.
Articles were identified on 2 other clinical trials with some
relevance, but both included OA and rheumatoid arthritis
patients and also proved to be inferior matches in other
respects [21,23]. We excluded the CLASS study from all
PUB analyses owing to controversies associated with the
study's ulcer-related results, and its use of 800 mg/d
celecoxib doses, which are quadruple the dose recom-
mended for OA patients. We compared POB RRs from
SUCCESS with those from the second best match, an arti-
cle on a pooled study of randomized clinical trials. How-
ever, this article did not report event rates for symptomatic
peptic ulcers or PUBs.
We also searched for observational studies that most
closely matched our criteria, given the dearth of relevant
celecoxib clinical trial data to compare with SUCCESS
probabilities. We wanted insights into adverse event rates
in the community, and POB or PUB rates over longer peri-
ods. Two case control studies involving celecoxib were
identified, one with average-risk patients and another
with high-risk patients [24,122]. Only the former was per-
tinent to the current analysis.
For clinical probabilities of dyspepsia, we sought articles
on clinical trials involving OA patients and comparing
nsNSAIDs and celecoxib at doses normally used in OA
patients, with relatively comprehensive definitions of dys-
pepsia, including related UGI symptoms, but excluding
heartburn as a dominant symptom. Our search used key
words "clinical trial" or "RCT," "dyspepsia," "abdominal
pain," "UGI discomfort" or "NUD," "celecoxib,"
"NSAIDs," and "arthritis." We identified 3 articles, but the
article based on CLASS was eliminated because suprather-
apeutic doses of celecoxib were used [32,34,35].
Various other searches were conducted including system-
atic searches on PubMed for all articles on the risks and
courses of dyspepsia, peptic ulcers, POBs, strokes and MIs
over extended periods. The objectives were to determine,
based on the best available evidence, how to model the
period prevalence rates, annual incidence rates, and dura-
tions of events over our analytic horizon, which extends
far beyond the durations of clinical trials. We searched the
literature systematically and manually for multivariate
analyses of the risk factors for peptic ulcers and POBs,
focusing especially on analyses with age as a continuous
variable or with multiple categorical age interval variables.
We also systematically reviewed other analyses powered
to provide breakdowns of RRs by age.
The searches for UGI events were last conducted in Janu-
ary 2005.
Appendix 2 – costs and disutilities of CV 
thromboembolic events
Health sector costs for first MIs or strokes included initial
hospitalizations, ongoing maintenance costs, and fore-
casted excess costs of future care [40,123-130]. Among
survivors, QALY decrements consisted of losses from ini-
tial hospital stays, ongoing postevent disutilities of 0.05
for MI survivors and 0.25 for stroke survivors, plus loss of
life expectancy assuming that mortality rates by age for
survivors were double the rates for the general population
[37,39,131-141]. The impacts of first-in-model events on
patients with a history of MI or stroke at baseline reflected
patients' premodel reductions in life expectancy, utilities,
and higher health sector costs [142-144]. The risks of CV
thromboembolic events were assumed to increase 5% per
year in sensitivity analyses that also assumed age-related
increases in the risks of UGI adverse events.
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